Vascular basis of Alzheimer's pathogenesis

Annals of the New York Academy of Sciences

Volumn 977, Issue , 2002, Pages 196-215

  De la Torre, J C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease (AD); Brain; Cerebral hypoperfusion; Vascular dementia (VaD); Vascular disorder

Indexed keywords

ACETYLCARNITINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; DIMETHYL SULFOXIDE; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; SELEGILINE; STATINE DERIVATIVE; TACRINE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ALZHEIMER DISEASE; BRAIN PERFUSION; COGNITION; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; HUMAN; MEMORY; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; RISK FACTOR; SYMPTOMATOLOGY; VASCULAR DISEASE;

GINKGO BILOBA;

EID: 0036447681     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04817.x     Document Type: Conference Paper

References (169)

1. de la Torre, J.C. & T. Mussivand. 1993. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol. Res. 15: 146-153.
2. de la Torre, J.C. 1994. Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci. Behav. Rev. 18: 397-401.
3. de la Torre, J.C. 1999. Critical threshold cerebral hypoperfusion causes Alzheimer's disease. Acta Neuropathol. 98: 1-8.
4. de la Torre, J.C. 2000. Critically-attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging 21(2): 331-342.
5. de la Torre, J.C. 1997. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann. N.Y. Acad. Sci. 826: 75-91.
6. de la Torre, J.C. & G.B. Stefano. 2000. Evidence that Alzheimer's disease is a microvascular disorder: Role of constitutive nitric oxide. Brain Res. Rev. 34: 119-136.
7. Breteler, M.M. 1998. Epidemiological evidence of a connection between Alzheimer's disease and vascular dementia. Neurobiol. Aging 19(4S): S150.
8. Breteler, M.M., M.L. Bots, A. Ott & A. Hofman. 1998. Risk factors for vascular disease and dementia. Haemostasis 28: 167-173.
9. Breteler, M.M. 2000. Vascular involvement in cognitive decline and dementia: Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N.Y. Acad. Sci. 903: 457-465.
10. Breteler, M.M. 2000. Vascular risk factors for Alzheimer's disease: An epidemiological study. Neurobiol. Aging 21: 153-160.
11. Ott, A., R.P. Stolk, A. Hofman et al. 1996. Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 39: 1392-1397.
12. Ott, A., R.P. Stolk, A. Hofman et al. 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1907-1909.
13. Bots, M.L., F. van Kooten, F. Haverkate et al. 1998. Coagulation and fibrinolysis markers and risk of dementia: The Dutch Vascular Factors in Dementia Study. Haemostasis 28: 216-222.
14. Kalmijn, S., L.J. Launer, J. Lindemans et al. 1999. Total homocysteine and cognitive decline in a community based sample of elderly subjects: The Rotterdam Study. Am. J. Epidemiol. 150: 283-289.
15. Ott, A., M.M. Breteler, M.C. de Bruyne et al. 1997. Atrial fibrillation and dementia in a population-based study: The Rotterdam Study. Stroke 28:316-321.
16. Ott, A., A.J. Slooter, A. Hofman et al. 1998. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study. Lancet 351: 1840-1843.
17. van Duijn, C.M., L.M. Havekes, C. van Broeckhoven et al. 1995. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. Br. Med. J. 310: 627-631.
18. Graves, A.B., C.M. van Duijn, V. Chandra et al. 1991. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative reanalysis of case-controlled studies - EURODEM Risk Factors Research Group. Int. J. Epidemiol. 20: S48-S57.
19. Ott, A., M.M. Breteler, F. van Harskamp et al. 1995. Prevalence of Alzheimer's disease and vascular dementia association with education: The Rotterdam Study. Br. Med. J. 310: 970-973.
20. Hofman, A., M.M. Breteler, M.L. Bots et al. 1997. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154.
21. Tyas, S.L., J. Manfreda, L.A. Strain & P.R. Montgomery. 2001. Risk factors for Alzheimer's disease: A population-based, longitudinal study in Manitoba, Canada. Int. J. Epidemiol. 30: 590-597.
22. Kalmijn, S. 1997. Dietary fat intake and risk of incident dementia in the Rotterdam Study. Ann. Neurol. 42: 776-782.
23. Davignon, J., R.E. Gregg & C.F. Sing. 1998. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8: 1-21.
24. Notkola, I.L., R. Sulkava, J. Pekkanen et al. 1998. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20.
25. Meyer, J.S., G. Rauch, R.A. Rauch & A. Haque. 2000. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol. Aging 21: 161-169.
26. Devanand, D.P., M. Sano, M. Tang et al. 1996. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch. Gen. Psychiatry 53: 175-182.
27. Geerlings, M.I., R.A. Schoevers, A. Beekman et al. 2000. Depression and risk of cognitive decline and Alzheimer's disease: Results of two prospective community-based studies in the Netherlands. Br. J. Psychiatry 176: 568-575.
28. Graves, A.B., C.M. van Duijn, V. Chandra et al. 1991. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative reanalysis of case-controlled studies - EURODEM Risk Factors Research Group. Int. J. Epidemiol. 20: S48-S57.
29. Diaz-Arrastia, R. 1998. Hyperhomocysteinemia: A new risk factor for Alzheimer's disease? Arch. Neurol. 55:1 2.
30. Seshadri, S., A. Beiser, J. Selhub et al. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346: 476-483.
31. Ohkura, T., K. Isse, K. Akazawa et al. 1994. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. Rev. 41:361-371.
32. Waring, S.C., W.A. Rocca et al. 1999. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 52: 965-970.
33. Ajmani, R.S., E.J. Metter, R. Jaycumar et al. 2000. Hemorheological changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiol. Aging 21: 257-270.
34. Solerte, S.B., E. Ferrari & M. Fioravanti. 2000. Hemorheologic changes and over-production of cytokines in mild to moderate dementia of the Alzheimer's type: Adverse effects on cerebrovascular system and therapeutic approach with pentoxifylline. Neurobiol. Aging 21: 271-282.
35. Fioravanti, M., W. Ricciardi, M. Cottinelli et al. 1998. Hemorheologic alterations and acute-phase reaction are related to recent-onset patients with senile dementia of the Alzheimer's type. Neurobiol. Aging 19(4S): S246-S247.
36. Morrison, R.A., A. McGrath, G. Davidson et al. 1996. Low blood pressure in Down's syndrome: A link with Alzheimer's disease? Hypertension 28: 569-575.
37. Passant, U., S. Warkentin & L. Gustafson. 1997. Orthostatic hypotension and low blood pressure in organic dementia: A study of prevalence and related clinical characteristics. Int. J. Geriatr. Psychiatry 12: 395-403.
38. Guo, Z., M. Viitanen, L. Fratiglioni & B. Winblad, 1997. Blood pressure and dementia in the elderly: Epidemiologic perspectives. Biomed. Pharmacother. 51: 68-73.
39. Jendroska, K., O.M. Hoffmann & S. Patt. 1997. Amyloid β peptide and precursor protein (APP) in mild and severe brain ischemia. Ann. N.Y. Acad. Sci. 826: 401-405.
40. Snowdon, D.A., L. Greiner, J. Mortimer et al. 1997. Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 277: 813-817.
41. Guo, Z., L.A. Cupples, A. Kurz et al. 2000. Head injury and the risk of AD in the MIRAGE study. Neurology 54: 1316-1323.
42. Plassman, B.L., R.J. Havlik et al. 2000. Documented head injury in early childhood and risk of Alzheimer's disease and other dementias. Neurology 55: 1158-1166.
43. Lye, T.C. & E.A. Shores. 2000. Traumatic brain injury as a risk factor for Alzheimer's disease: A review. Neuropsychol. Rev. 10: 115-129.
44. Kilander, L., B. Andren, H. Nyman et al. 1998. Atrial fibrillation is an independent determinant of low cognitive function: A cross-sectional study in elderly men. Stroke 29: 1816-1820.
45. Deklunder, G., M. Roussel, J.L. Lecroart et al. 1998. Microemboli in cerebral circulation and alteration of cognitive abilities in patients with mechanical prosthetic heart valves. Stroke 29: 1821-1826.
46. Amaducci, L.A., A. Lippi & L. Fratiglioni. 1988. What risk factors are known? In Etiology of Dementia of Alzheimer's Type, pp. 29-37. Plenum. New York
47. Maxwell, A.J. 2002. Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide Biol. Chem. 6: 101-124.
48. Kalaria, R.N. & C. Ballard. 1999. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13(suppl. 3): S115-S123.
49. Skoog, I. 1999. Vascular factors in dementia. Alzheimer Dis. Assoc. Disord. 13(suppl. 3): S106-S114.
50. Groves, W.C., J. Brandt, M. Steinberg et al. 2000. Vascular dementia and Alzheimer's disease: Is there a difference? A comparison of symptoms by disease duration. J. Neuropsychiatry Clin. Neurosci. 12(3): 305-315.
51. Villardita, C, 1993. Alzheimer's disease compared with cerebrovascular dementia: Neuropsychological similarities and differences. Acta Neurol. Scand. 87: 299-308.
52. Launer, L.J., G.W. Ross, H. Petrovich et al. 2000. Midlife blood pressure and dementia: The Honolulu-Asia Aging Study. Neurobiol. Aging 21: 49-55.
53. Kivipelto, M., E.L. Helkala et al. 2001. Midlife vascular risk factors and late-life cognitive impairment: A population-based study. Neurology 56: 1683-1689.
54. Korczyn, A.D. 2002. Mixed dementia - The most common cause of dementia. Ann. N.Y. Acad. Sci. This volume.
55. Broe, G.A., D.A. Grayson, H. Creasey et al. 2000. Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch. Neurol. 57: 1586-1591.
56. Le Bars, P.L., M. Kieser & K. Itil. 2000. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract Egb 761 in dementia. Dement. Geriatr. Cogn. Disord. 11: 230-237.
57. Forstl, H. 2000. Clinical issues in current drug therapy for dementia. Alzheimer Dis. Assoc. Disord. 14(suppl. 1): S103-S108.
58. Losordo, D.W. & J.M. Isner. 2001. Estrogen and angiogenesis: A review. Arterioscler, Thromb. Vasc. Biol. 21: 6-12.
59. Ohkura, T., K. Isse, K. Akazawa et al. 1994. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. J. 41:361-371.
60. Waring, S.C., W.A. Rocca et al. 1999. Postmenopausal estrogen replacement therapy and risk of AD: A population-based study. Neurology 52: 965-970.
61. Groppa, S.A. 1994. New possibilities in the treatment of patients with Alzheimer's disease. Neurobiol. Aging 15: S101.
62. Breitner, J.C., B.A. Gau, K.A. Welsh, et al. 1994. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 44: 227-232.
63. Sano, M., C. Ernesto, R.G. Thomas et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Co-operative Study. N. Engl. J. Med. 336: 1216-1222.
64. Reichman, W.E. 2000. Alzheimer's disease: Clinical treatment options. Am. J. Manag. Care 22: S1125-S1132.
65. Pettegrew, J.W., J. Levine & R.J. McClure. 2000. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry 5: 616-632.
66. Postiglione, A., A. Soricelli, U. Cicerano et al. 1991. Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. Pharmacol. Res. 23: 242-246.
67. In't Veld, B.A., A. Ruitenberg, A. Hofman et al. 2001. Antihypertensive drugs and incidence of dementia: The Rotterdam Study. Neurobiol. Aging 22: 407-412.
68. Jick, H., G. Zornberg, S.S. Jick et al. 2000. Statins and the risk of dementia. Lancet 356(9242): 1627-1631.
69. Wolozin, B., W. Kellman, P. Ruosseau et al. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57: 1439-1443.
70. Thomas, T. 2000. Monoamine oxidase-β-inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging 21: 343-348.
71. Bozoki, A., B. Giordani, J.L. Heidebrink et al. 2001. Mild cognitive impairments predict dementia in non-demented elderly patients with memory loss. Arch. Neurol. 58: 411-416.
72. Morris, J.C., M. Storandt, J.P. Miller et al. 2001. Mild cognitive impairment represents early stage Alzheimer's disease. Arch. Neurol. 58: 397-405.
73. Shah, S., E.G. Tangalos & R. Petersen. 2000. Mild cognitive impairment: When is it a precursor of Alzheimer's disease? Geriatrics 55: 65-68.
74. Johnson, K.A., K. Jones, B.L. Holman et al. 1998. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50: 1563-1571.
75. Johnson, K.A. & M.S. Albert. Perfusion abnormalities in prodromal Alzheimer's disease. Neurobiol. Aging 21: 289-292.
76. Kogure, D., H. Matsuda, T. Ohnishi et al. 2000. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J. Nucl. Med. 41: 1155-1162.
77. Okamura, N., M. Shinkawa, H. Arai et al. 2000. Prediction pf progression in patients with mild cognitive impairment using IMP-SPECT. Nippon Ronen Igakkai Zasshi 37: 974-978.
78. Rodriguez, G., P. Vitali, P. Calvini et al. 2000. Hippocampal perfusion in mild cognitive impairment. Psychiatry Res. 100: 65-74.
79. De Santi, S., M.J. de Leon, H. Rusinek et al. 2001. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 22: 529-539.
80. Arnaiz, E., V. Jelic, O. Almkvist et al. 2001. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12: 851-855.
81. de Leon, M., A. Convit, O.T. Wolf et al. 2001. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]-fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U.S.A. 98: 10966-10971.
82. Bowler, J.V., M. Eliasziw et al. 1997. Comparative evolution of Alzheimer's disease, vascular dementia, and mixed dementia. Arch. Neurol. 54: 697-703.
83. Ransmayr, G. 1998. Difficulties in the clinical diagnosis of vascular dementia and dementia of the Alzheimer type: comparison of clinical classifications. J. Neural Transm. 53: 79-90.
84. Aguero-Torres, H. & B. Winblad. 2000. Alzheimer's disease and vascular dementia: Some points of confluence. Ann. N.Y. Acad. Sci. 903: 547-552.
85. Wallin, A. 1998. The overlap between Alzheimer's disease and vascular dementia: The role of white matter changes. Dement. Geriatr. Cogn. Disord. 1: 30-35.
86. Scheltens, P. & E.S. Korf. 2000. Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr. Opin. Neurol. 13: 391-396.
87. Barber, R., P. Scheltens, A. Gholkar et al. 1999. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J. Neurol. Neurosurg. Psychiatry 67: 66-72.
88. Tarkowski, E., K. Blennow, A. Wallin & A. Tarkowski. 1999. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer's disease and vascular dementia. J. Clin. Immunol. 19: 223-230.
89. Parnetti, L., G.P. Reboldi & V. Gallai. 2000. Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. Neurology 54: 735-737.
90. Carantoni, M., G. Zuliani, M. Munari et al. 2000. Alzheimer disease and vascular dementia: Relationship with fasting glucose and insulin levels. Dement. Geriatr. Cogn. Disord. 11: 176-180.
91. Ellis, R.J., J.M. Olichney, L. Thal et al. 1996. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience - Part XV. Neurology 46: 1592-1596.
92. Rosengren, L.E., J.E. Karlsson, M. Sjogren et al. 1999. Neurofilament protein levels in CSF are increased in dementia. Neurology 52: 1090-1093.
93. Rodriguez, M.T., A.M. Calella, S. Silva & E. MUNNA. 2000. Apolipoprotein E and intronic polymorphism of presenilin 1 and alpha-1-antichymotrypsin in Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord. 11: 239-244.
94. Zhang, J.G., J.G. Yang, Z. Lin et al. 2001. Apolipoprotein E epsilon 4 allele is a risk factor for late-onset Alzheimer's disease and vascular dementia in Han Chinese. Int. J. Geriatr. Psychiatry 16: 438-439.
95. Bonarek, M., P. Barberger-Gateau et al. 2000. Relationship between cholesterol, apolipoprotein E polymorphism, and dementia: A cross-sectional analysis from the PAQUID Study. Neuroepidemiology 19: 141-148.
96. Wehr, H., T. Parnowski, S. Puzynski et al. 2000. Apolipoprotein E genotype and lipid lipoprotein levels in dementia. Dement. Geriatr. Cogn. Disord. 11: 70-73.
97. Kalaria, R.N., H.D. Lewis, N. Thomas & S. Shearman. 1999. Brain Aβ42 and Aβ40 concentrations in multi-infarct dementia and Alzheimer's disease. Soc. Neurosci. Abstr. 23: 1114.
98. Ballard, C., J. O'Brien, C.M. Morris et al. 2001. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia, and Alzheimer's disease. Int. J. Geriatr. Psychiatry 16: 499-503.
99. Holmes, C., N. Cairns, P. Lantos & A. Mann. 1999. Validity of current clinical criteria for Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Br. J. Psychiatry 174: 45-50.
100. O'Brien, J.T., S. Paling, R. Barber et al. 2001. Progressive brain atrophy on serial MR1 in dementia with Lewy bodies, Alzheimer's, and vascular dementia. Neurology 56: 1386-1388.
101. Morris, J.C. 2000. The nosology of dementia. Neurol. Clin. 18: 773-788.
102. Dickson, D.W. 2001. Neuropathology of Alzheimer's disease and other dementias. Clin. Geriatr. Med. 17: 209-228.
103. Erkinjuntti, T. 2001. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int. J. Clin. Pract. 120: 14-23.
104. Wentzel, C., S. Darvesh, C. Macknight et al. 2000. Inter-rater reliability of the diagnosis of vascular cognitive impairment at a memory clinic. Neuroepidemiology 19: 186-193.
105. Roman, G. 2001. Diagnosis of vascular dementia and Alzheimer's disease. Int. J. Clin. Pract. 120: 9-13.
106. Chui, H.C., W. Mack, J.E. Jackson et al. 2000. Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability. Arch. Neurol. 57: 191-196.
107. Tarkowski, E., K. Blennow, A. Wallin & A. Tarkowski. 1999. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer's disease and vascular dementia. J. Clin. Immunol. 19: 223-230.
108. De Jong, G.I., R.A.I. De Vos, E. Janssen-Steur & P.G. Luiten. 1997. Cerebro-vascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann. N.Y. Acad. Sci. 826: 56-74.
109. Hatanpää, K. 1996. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 40: 411-420.
110. Duara, R., W.W. Barker, J. Chang & F. Yoshu. 1992. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer's disease. J. Cereb. Blood Flow Metab. 12: 927-934.
111. Davis, D.G., F.A. Schmitt, D. Wekstein & W.R. Markesbery. 1999. Alzheimer neuropatholoic alterations in aged cognitively normal subjects. J. Neuropathol. Exp. Neurol. 58: 376-388.
112. Buee, L., P.R. Hoe, C. Bouras et al. 1994. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related demented disorders. Acta Neuropathol. 87: 469-480.
113. Jones, A.M., N. Kennedy, J. Hanson & G.W. Fenton. 1997. A study in adults with Down's syndrome using 99Tc(m)-HMPAO SPET. Nucl. Med. Commun. 18: 662-667.
114. Kao, C.H., P.Y. Wang, S.J. Wang et al. 1993. Regional cerebral blood flow of Alzheimer's disease-like pattern in young patients with Down's syndrome detected by 99Tcm-HMPAO brain SPECT. Nucl. Med. Commun. 14: 47-51.
115. Nunomura, A., G. Perry et al. 2000. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59: 1011-1017.
116. de la Torre, J.C., A. Cada et al. 1997. Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. Neurosci. Lett. 223: 165-168.
117. Abdollahian, N.P., A. Cada, F. Gonzalez-Lima & J.C. de la Torre. 1998. Cytochrome oxidase: A predictive marker of neurodegeneration. In Cytochrome Oxidase in Neuronal Metabolism and Alzheimer's Disease, pp. 233-261. Plenum. New York.
118. Tanaka, K., N. Wada & N. Ogawa. 2000. Chronic cerebral hypoperfusion induces transient reversible monoaminergic changes in the rat brain. Neurochem. Res. 25: 313-320.
119. Ouchi, Y., H. Tsukada, T. Kakiuchi et al. 1998. Changes in cerebral blood flow and postsynaptic muscarinic activity in rats with bilateral carotid artery ligation. J. Nucl. Med. 39: 198-202.
120. Otori, T., T. Katsumata, Y. Katayama & A. Terashi. 1997. Measurement of regional cerebral blood flow and glucose utilization in rat brain under chronic hypoperfusion conditions following bilateral carotid artery occlusion. Nippon Ika Daigaku Zasshi 64: 428-439.
121. Tsuchiya, M., K. Sako, S. Yura & Y. Yonemasu. 1993. Local cerebral glucose utilization following acute and chronic bilateral carotid artery ligation in Wistar rats: Relation to changes in local cerebral blood flow. Exp. Brain Res. 95: 1-7.
122. de la Torre, J.C., T. Fortin et al. 1992. Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res. 582: 186-195.
123. Pappas, B.A., C. Davidson, S. Bennett et al. 1997. Chronic ischemia: Memory impairment and neural pathology in the rat. Ann. N.Y. Acad. Sci. 826: 498-501.
124. Ihara, M., H. Tomimoto, M. Kinoshita et al. 2001. Chronic cerebral hypoperfusion induces MMP-2, but not MMP-9 expression in the microglia and vascular endothelium of white matter. J. Cereb. Blood Flow Metab. 21: 828-834.
125. Tanaka, K., N. Wada, K. Hori et al. 1998. Chronic cerebral hypoperfusion disrupts discriminative behavior in acquired-learning rats. J. Neurosci. Methods 84: 63-68.
126. Ni, J.W., H. Ohta, K. Matsumoto & H. Watanabe. 1994. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res. 653: 231-236.
127. Burmester, T., B. Weich, S. Reinhardt & T. Hankeln. 2000: A vertebrate globin expressed in the brain. Nature 407(6803): 461-462.
128. de la Torre, J.C. 2000. Impaired cerebromicrovascular perfusion: Summary of evidence in support of its causality in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924: 136-152.
129. de la Torre, J.C. 2000. Cerebral perfusion, capillary degeneration, and development of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 14: S72-S81.
130. Martin, A.J., K.J. Friston, J.G. Colebatch & R. Frackowiak. 1991. Decreases in regional cerebral blood flow with normal aging. J. Cereb. Blood Flow Metab. 11: 684-689.
131. Small, S.A., W. Tsai et al. 2002. Imaging hippocampal function across the human life span: Is memory decline normal or not? Ann. Neurol. 51: 290-295.
132. Erecinska, M. & I. Silver. 1989. ATP and brain function. J. Cereb. Blood Flow Metab. 9: 2-12.
133. Lehmann, M., C.G. Gottfries & B. Regland. 1999. Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Dement. Geriatr. Cogn. Dis. 10: 12-20.
134. Meier-Ruge, W. & C. Bertoni-Freddari. 1996. The significance of glucose turnover in the brain in the pathogenic mechanisms of Alzheimer's disease. Rev. Neurosci. 7: 1-19.
135. Paschen, W., K.C. Gissel., T. Linden et al. 1998. Activation of gadd153 expression through transient cerebral ischemia: Evidence that ischemia causes endoplasmic reticulum dysfunction. Brain Res. Mol. Brain Res. 18: 115-122.
136. Paschen, W. & J. Doutheil. 1999. Disturbances of the functioning of endoplasmic reticulum: A key mechanism underlying neuronal cell injury? J. Cereb. Blood Flow Metab. 19: 1-18.
137. Abe, K., M. Aoki, J. Kawagoe et al. 1995. Ischemic delayed neuronal death: a mitochondrial hypothesis. Stroke 26: 1478-1489.
138. Kakimura, J., Y. Kitamura & T. Taniguchi. 2001. Bip/GRP78-induced production of cytokines and uptake of amyloid-β(1-42) peptide in microglia. Biochem. Biopbys. Res. Commun. 28: 6-10.
139. Scheller, R.H. & Z.W. Hall. 1992. Chemical messengers at synapses. In Molecular Neurobiology, pp. 119-147. Sinauer Associates. Sunderland, MA.
140. Greenfield, J.P., J. Tsai, G.K. Gouras et al. 1999. Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Proc. Natl. Acad. Sci. U.S.A. 96: 742-747.
141. Hartmann, T., S.C. Bieger et al. 1997. Distinct sites of intracellular production of Alzheimer's disease Aβ40/42 amyloid peptides. Nat. Med. 3: 1016-1020.
142. Pike, C.J., M.J. Overman & C. Cotman. 1995. Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. J. Biol. Chem. 270: 23895-23898.
143. Chen, Y., S. Weii, Z. Mourelatos et al. 1998. The fragmented neuronal Golgi apparatus in ALS includes the trans-Golgi-network: functional implications. Acta Neuropatbol. 95: 245-253.
144. Hammerschlag, R. & G.C. Stone. 1982. Membrane delivery by fast axonal transport. Trends Neurosci. 5: 12-15.
145. Stieber, A., Z. Mourelatos & N.K. Gonatas. 1996. In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am. J. Pathol. 148: 415-426.
146. Stieber, A., Y. Chen, S. Wei et al. 1998. The fragmented neuronal Golgi apparatus in amyotrophic lateral sclerosis includes the trans-Golgi-network: Functional implications. Acta Neuropathol. 95: 245-253.
147. Mufson, E.J., J.S. Kroin, T.J. Sendera & T. Sobreviela. 1999. Distribution and retrograde transport of trophic factors in the central nervous system: Functional implications for the treatment of neurodegenerative disease. Prog. Neurobiol. 57: 451-484.
148. Luth, H.J., M. Holzer, U. Gartner et al. 2001. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice, and after experimental brain lesion in rat: Evidence for an induction by amyloid pathology. Brain Res. 913: 57-67.
149. Lee, T.J. 2000. Nitric oxide and cerebral vascular function. J. Biomed. Sci. 7: 16-26.
150. Huang, Z., P.L. Huang, N. Panahian et al. 1994. Effects of cerebral ischemia in mice deficient of neuronal nitric oxide synthase. Science 265: 1883-1885.
151. Kubes, P. & D. Granger. 1992. Nitric oxide modulates microvascular permeability. Am. J. Physiol. 262: H611-H615.
152. Kubes, P., S. Kanwar & X.F. Niu. 1993. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J. 7: 1293-1299.
153. Niu, X.F., C.W. Smith & P. Kubes. 1995. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ. Res. 74: 1133-1140.
154. Napoli, C. & L.J. Ignarro. 2001. Nitric oxide and atherosclerosis. Nitric Oxide 5: 88-97.
155. Schini-Kerth, V.B. 1999. Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis. Transfus. Clin. Biol. 6: 355-363.
156. Malek, A.M., S. Izumo & S.L. Alper. 1999. Modulation by pathophysiological stimuli of the shear stress - Induced up-regulation of endothelial nitric oxide synthase expression in endothelial cells. Neurosurgery 45: 334-345.
157. 2+ mobilization and cytoskeletal F-actin filaments in human cerebro-microvascular endothelial cells. J. Cereb. Blood Flow Metab. 19: 133-138.
158. Blackwell, T.S., T.R. Blackwell et al. 1996. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J. Immunol. 157: 1630-1637.
159. Siebenlist, U., G. Franzoso & K. Brown. 1994. Structure, regulation, and function of NF-kappa B. Annu. Rev. Cell Biol. 10: 405-455.
160. Ledebur, H.C. & T.P. Parks. 1995. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells: Essential roles of a variant NF-kappa B site and p65 homodimers. J. Biol. Chem. 270: 933-943.
161. Chen, C.C., C.L. Rosenbloom, D.C. Anderson & A.M. Manning. 1995. Selective inhibition of E-selectin, vascular cell adhesion molecule- 1, and intercellular adhesion molecule-1 expression by inhibitors of I-kappa B-alpha phosphorylation. J. Immunol. 155: 3538-3545.
162. Read, M.A., M.Z. Whitley, A.J. Williams & T. COLLINS. 1994. NF-kappa B and 1 kappa B alpha: an inducible regulatory system in endothelial activation. J. Exp. Med. 179: 503-512.
163. Shin, W.S., Y.H. Hong, H.B. Peng et al. 1996. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma: the role of constitutive NF-kappa B activity. J. Biol. Chem. 71: 11317-11324.
164. Peng, H.B., P. Libby & J.K. Liao. 1995. Induction and stabilization of I kappa B alpha by nitric oxide mediate inhibition of NF-kappa B. J. Biol. Chem. 270: 14214-14219.
165. Welters, I., C. Fimiani., T.V. Bilfinger & G.B. Stefano. 2000. NF-kB, nitric oxide, and opiate signaling. Med. Hypotheses 54: 263-268.
166. Xie, Q. & C. Nathan. 1994. The high-output nitric oxide pathway: Role and regulation. J. Leukocyte Biol. 56: 576-582.
167. Matthews, J.R., C.H. Botting, M. Panico et al. 1996. Inhibition of NF-kappa B DNA binding by nitric oxide. Nucleic Acids Res. 24: 2236-2242.
168. de la Torre, J.C. 2002. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33: 1152-1162.
169. de la Torre, J.C. 1997. Hemodynamics of deformed microvessels in Alzheimer's disease brain. Ann. N.Y. Acad. Sci. 826: 75-91.